Hologic (HOLX) Expected to Announce Earnings on Wednesday

Hologic (NASDAQ:HOLX) will likely be announcing its earnings results after the market closes on Wednesday, February 5th. Analysts expect the company to announce earnings of $1.02 per share and revenue of $1.02 billion for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same period in the prior year, the firm earned $0.89 EPS. The business’s revenue was up 4.5% on a year-over-year basis. On average, analysts expect Hologic to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Hologic Price Performance

Shares of Hologic stock opened at $71.72 on Tuesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. Hologic has a fifty-two week low of $68.61 and a fifty-two week high of $84.67. The firm has a fifty day moving average price of $73.19 and a two-hundred day moving average price of $78.03. The company has a market cap of $16.19 billion, a PE ratio of 21.54, a price-to-earnings-growth ratio of 2.35 and a beta of 0.98.

Insider Activity at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.88% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have weighed in on HOLX shares. BNP Paribas raised shares of Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Leerink Partners reduced their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. William Blair reaffirmed an “outperform” rating on shares of Hologic in a report on Monday, January 13th. Wolfe Research initiated coverage on shares of Hologic in a report on Friday, December 13th. They set a “peer perform” rating for the company. Finally, JPMorgan Chase & Co. raised their price objective on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Eight analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Hologic has an average rating of “Moderate Buy” and a consensus target price of $88.92.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.